Benefit in lung function improvement and side-effect profile of long-term responders: An analysis of 14 NSCLC patients treated for at least 9 months with gefitinib
- 31 October 2005
- journal article
- clinical trial
- Published by Elsevier BV in Lung Cancer
- Vol. 50 (1), 107-114
- https://doi.org/10.1016/j.lungcan.2005.05.006
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With ChemotherapyJournal of Clinical Oncology, 2004
- American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003Journal of Clinical Oncology, 2004
- Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung CancerJAMA, 2003
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2003
- End Points and United States Food and Drug Administration Approval of Oncology DrugsJournal of Clinical Oncology, 2003
- A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancerLung Cancer, 2003
- ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC)Published by Elsevier BV ,2001
- Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy RegimensJournal of Clinical Oncology, 2000
- Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based ChemotherapyJournal of Clinical Oncology, 2000
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000